ConductScience.org, home

Trial · NCT01474122

Results by group27

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Incidence Rate of New Digital Ulcers (DUs) up to Week 16Macitentan 3mg1.4413new DUs/16 weeks
Incidence Rate of New Digital Ulcers (DUs) up to Week 16Macitentan 10mg1.3636new DUs/16 weeks
Incidence Rate of New Digital Ulcers (DUs) up to Week 16Placebo1.1049new DUs/16 weeks
Percentage of Participants Without a New DU up to Week 16Macitentan 3mg56.0Percentage of participants
Percentage of Participants Without a New DU up to Week 16Macitentan 10mg54.8Percentage of participants
Percentage of Participants Without a New DU up to Week 16Placebo59.8Percentage of participants
Percentage of Participants With at Least One DU ComplicationMacitentan 3mg21.4Percentage of participants
Percentage of Participants With at Least One DU ComplicationMacitentan 10mg19.0Percentage of participants
Percentage of Participants With at Least One DU ComplicationPlacebo18.4Percentage of participants
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16Macitentan 3mgBaseline1.4Standard Deviation 0.73Units on a scale
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16Macitentan 10mgBaseline1.3Standard Deviation 0.70Units on a scale
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16PlaceboBaseline1.4Standard Deviation 0.72Units on a scale
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16Macitentan 3mgWeek 161.2Standard Deviation 0.75Units on a scale
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16Macitentan 10mgWeek 161.1Standard Deviation 0.76Units on a scale
Change in Hand Functionality Health Assessment Questionnaire - Disability Index (HAQ-DI) Hand Component From Baseline to Week 16PlaceboWeek 161.3Standard Deviation 0.77Units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Overall Score From Baseline to Week 16Macitentan 3mgBaseline1.2Standard Deviation 0.67Units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Overall Score From Baseline to Week 16Macitentan 10mgBaseline1.1Standard Deviation 0.65Units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Overall Score From Baseline to Week 16PlaceboBaseline1.2Standard Deviation 0.66Units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Overall Score From Baseline to Week 16Macitentan 3mgWeek 161.1Standard Deviation 0.70Units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Overall Score From Baseline to Week 16Macitentan 10mgWeek 161.0Standard Deviation 0.71Units on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01474122/results